Mencord

Olmesartan Medoxomil, the active ingredient in Mencord, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension by selectively antagonising AT1 receptors that mediate vasoconstriction.

GNH USA supplies Mencord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches that meet EU regulatory standards. The company efficiently handles export logistics, documentation and post‑delivery support for customers worldwide.

Olmesartan Medoxomil is an angiotensin II receptor blocker used in the management of hypertension.

- Hypertension: lowers systolic and diastolic blood pressure and reduces the risk of cardiovascular events.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure sensation. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated potassium levels in blood tests. - Increased serum creatinine: mild rise indicating renal adaptation.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing fainting. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: abnormal liver enzymes indicating liver stress.

Olmesartan Medoxomil should be used with careful clinical monitoring.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Pregnancy and lactation: avoid use because safety is not established. - Drug interactions: review all concomitant medications for potential additive effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal impairment. - Dual blockade with ACE inhibitors or other ARBs: may cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and affect kidney function. - Lithium: increased lithium levels, monitor for toxicity. - Cyclosporine or tacrolimus: may elevate serum creatinine, watch renal parameters. - Other antihypertensives: additive blood pressure‑lowering effect, adjust dose as needed.